Cryptotanshinone enhances the efficacy of Bcr-Abl tyrosine kinase inhibitors via inhibiting STAT3 and eIF4E signalling pathways in chronic myeloid leukaemia

• Autores principales: Rubin Cheng (Autor), Yilan Huang (Autor), Yun Fang (Autor), Qirui Wang (Autor), Meixiu Yan (Autor), Yuqing Ge (Autor)
• Formato: Libro
• Publicado: Taylor & Francis Group, 2021-01-01T00:00:00Z.
• Materias: article
• Acceso en línea: Connect to this object online.

Context A portion of patients with chronic myeloid leukaemia (CML) develop resistance to the Bcr-Abl tyrosine kinase inhibitors (TKIs), limiting the clinical applications. Previous results have demonstrated the synergistic effects between cryptotanshinone (CPT) and imatinib on apoptosis of CML cells...